Liquidia Q3 2026: A $389.7M Charge Masks a Booming YUTREPIA Quarter

Liquidia's Q3 2026 results split cleanly into two stories. On the commercial side, YUTREPIA net product sales reached $222.7 million, up 31% sequentially, pushing total revenue to $225.3 million and beating the consensus estimate of $214.1 million. Year over year, revenue surged 314.6%, a pace that would have made this one of the company's strongest quarters on record.

The GAAP earnings per share figure of negative $2.64 tells a different story, missing the consensus estimate of $0.98. That gap is almost entirely the product of a single line item: a $389.7 million litigation settlement charge tied to Liquidia's global resolution with United Therapeutics and Treprostinil Injection antitrust parties. A $30.1 million income tax benefit partially offset the hit, leaving a GAAP net loss of $236.3 million for the quarter.

The settlement carries a concrete operational consequence beyond the charge itself. YUTREPIA's label is being restricted to PAH, removing the PH-ILD indication. That narrows the drug's addressable market, at least until pipeline candidates such as L606 can pursue PH-ILD through separate clinical programs. CEO Roger Jeffs framed the resolution as a turning point: "With the litigation now fully resolved, and YUTREPIA's commercial availability secure, we can fully focus on cementing the value of YUTREPIA through Phase 4 studies in PAH that will position it as the best-in-class inhaled therapy and first-in-choice prostacyclin."

The funding math is tight. Liquidia must pay $380.7 million in net settlement installments across 2026 and 2027, against a cash position of $396.1 million as of the end of Q3. Management expects ongoing YUTREPIA revenue to cover the gap, which makes the drug's growth trajectory the single most important variable to monitor. The prescriber base stood at 1,300 at quarter-end, with conversion from referral to patient start holding above 87%, and October 2026 total patient shipments reached their highest monthly level since launch.

Investors looking past the settlement will find a company with an active clinical agenda. The SPRINT hemodynamic study of higher-frequency YUTREPIA dosing was set to initiate in Q4 2026, while the L606 pivotal PH-COPD study is targeted for the second half of 2027. The company also received FDA Fast Track designation for YUTREPIA in SSc-RP in September 2026, an indication with no currently approved treatments. What the next several quarters will reveal is whether YUTREPIA's commercial momentum can sustain a business simultaneously servicing a large settlement obligation and funding that pipeline.